SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Posaconazole Injection Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Posaconazole Injection Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
             Kilsheelan
             Clonmel Tipperary, IE
   Telephone : 353-51-601000
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   +1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Skin sensitisation, Category 1 : H317: May cause an allergic skin reaction.
   Specific target organ toxicity - repeated exposure, Category 2 : H373: May cause damage to organs through prolonged or repeated exposure.
   Long-term (chronic) aquatic hazard, Category 3 : H412: Harmful to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms :
   Signal word : Warning
   Hazard statements : H317: May cause an allergic skin reaction.
                      H373: May cause damage to organs through prolonged or repeated exposure.
                      H412: Harmful to aquatic life with long lasting effects.
   Precautionary statements : Prevention:
Posaconazole Injection Formulation

P272 Contaminated work clothing should not be allowed out of the workplace.
P273 Avoid release to the environment.
P280 Wear protective gloves.

Response:
P314 Get medical advice/attention if you feel unwell.
P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Hazardous components which must be listed on the label:
.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts
Posaconazole

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts</td>
<td>182410-00-0 417-710-5</td>
<td>Skin Sens. 1; H317</td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>171228-49-2</td>
<td>Eye Irrit. 2; H319 Rep. 2; H361d STOT RE 1; H372 (Adrenal gland, Bone marrow, Kidney, Liver, Nervous system, Reproductive organs) Aquatic Acute 1; H400 Aquatic Chronic 1;</td>
<td>&gt;= 1 - &lt; 2,5</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Posaconazole Injection Formulation

Version 6.4 Revision Date: 09.04.2021 SDS Number: 22513-00019 Date of last issue: 04.01.2021 Date of first issue: 16.10.2014

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Symptoms: Diarrhoea
Fever
Headache
Nausea
Vomiting

Risks: May cause an allergic skin reaction. May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.
SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
- None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting:
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Sulphur oxides
- Metal oxides

5.3 Advice for firefighters
Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions
Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate contain-
ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases
SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posaconazole</td>
<td>171228-49-2</td>
<td>TWA</td>
<td>300 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment
Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection  : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.
Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to NS EN 143
Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : Aqueous solution
Colour : Colorless to pale yellow
Odour : Odourless
Odour Threshold : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
## Section 9: Physical and Chemical Properties

### Flammability
- Flammability (solid, gas): Not applicable
- Flammability (liquids): No data available
- Upper explosion limit / Upper flammability limit: No data available
- Lower explosion limit / Lower flammability limit: No data available
- Flash point: No data available
- Auto-ignition temperature: No data available
- Decomposition temperature
  - Decomposition temperature: No data available
  - pH: 2.6
- Viscosity
  - Viscosity, kinematic: No data available
- Solubility(ies)
  - Water solubility: No data available
- Partition coefficient: n-octanol/water: Not applicable
- Vapour pressure: No data available
- Relative density: No data available
- Density: 1.15 g/cm³
- Relative vapour density: No data available
- Particle characteristics
  - Particle size: Not applicable

### Other Information
- Explosives: Not explosive
- Oxidizing properties: The substance or mixture is not classified as oxidizing.
- Evaporation rate: No data available
- Molecular weight: No data available

## SECTION 11: Stability and Reactivity

### Reactivity
Not classified as a reactivity hazard.
10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:
- .beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:
  Acute oral toxicity: LD50 (Rat): > 8.800 mg/kg

Posaconazole:
- Acute oral toxicity: LD50 (Rat): > 5.000 mg/kg
  LD50 (Mouse): > 3.000 mg/kg
- Acute dermal toxicity: LD50 (Rat): > 2.000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
- Posaconazole:
  Species: Rabbit
  Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.
Components:

Posaconazole:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation
Skin sensitisation
May cause an allergic skin reaction.
Respiratory sensitisation
Not classified based on available information.

Components:
.
.
.

Beta-Cyclodextrin, sulfobutyl ethers, sodium salts:
Assessment: Probability or evidence of skin sensitisation in humans

Posaconazole:
Test Type: Magnusson-Kligman-Test
Exposure routes: Skin contact
Species: Guinea pig
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Posaconazole:
Genotoxicity in vitro
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: Chromosomal aberration
Result: negative
Genotoxicity in vivo
Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Intravenous
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Posaconazole:
Species: Rat
Application Route: Oral (feed)
Exposure time: 2 Years
Result: positive
### Reproductive toxicity
Not classified based on available information.

#### Components:

**.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:**
- **Effects on fertility**
  - Test Type: Fertility
  - Species: Rat
  - Application Route: Intravenous injection
  - Result: negative

### Posaconazole:

#### Effects on fertility
- Test Type: Fertility/early embryonic development
  - Species: Rat, male
  - General Toxicity - Parent: NOAEL: 180 mg/kg body weight
  - Symptoms: No effects on mating performance
  - Result: negative

- Test Type: Fertility/early embryonic development
  - Species: Rat, female
  - General Toxicity - Parent: NOAEL: 45 mg/kg body weight
  - Symptoms: No effects on mating performance
  - Result: negative

#### Effects on foetal development
- Test Type: Embryo-foetal development
  - Species: Rat, female
  - Developmental Toxicity: LOAEL: 29 mg/kg body weight
  - Result: Fetotoxicity, Malformations were observed.

- Test Type: Embryo-foetal development
  - Species: Rabbit, female
  - Developmental Toxicity: LOAEL: 40 mg/kg body weight
  - Result: Fetotoxicity

#### Reproductive toxicity - Assessment
- Some evidence of adverse effects on development, based on animal experiments.
STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

**Posaconazole:**

<table>
<thead>
<tr>
<th>Exposure routes</th>
<th>Ingestion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Organs</td>
<td>Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system</td>
</tr>
<tr>
<td>Assessment</td>
<td>Causes damage to organs through prolonged or repeated exposure.</td>
</tr>
</tbody>
</table>

Repeated dose toxicity

**Components:**

**Posaconazole:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat, female</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>5 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>3 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>392 Days</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>15 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>1 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Bone marrow, Adrenal gland, Lymph nodes, Blood</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>3 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>56 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>180 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>12 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Blood, Gastrointestinal tract, spleen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>8 mg/kg</td>
</tr>
</tbody>
</table>
Posaconazole Injection Formulation

Application Route: Intravenous
Exposure time: 1 Months
Target Organs: Cardio-vascular system, Lungs, Adrenal gland, Blood

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Posaconazole:
Ingestion: Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia, electrolyte imbalance

SECTION 12: Ecological information

12.1 Toxicity

Components:

.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 220 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 96 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Selenastrum capricornutum (green algae)): > 100 mg/l
Exposure time: 72 h

Posaconazole:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 0,95 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0,276 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)) > 0.509 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity): 1

Toxicity to microorganisms: EC50 (Natural microorganism): > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity): NOEC: 0.206 mg/l
Exposure time: 33 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0.244 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity): 1

12.2 Persistence and degradability

Components:

Posaconazole:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 h
Method: OECD Test Guideline 314

Stability in water: Degradation half life (DT50): > 30 d
Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

Components:

Posaconazole:
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 20
Method: OECD Test Guideline 305
12.4 Mobility in soil

**Components:**

**Posaconazole:**

Distribution among environmental compartments : log Koc: 5.52

12.5 Results of PBT and vPvB assessment

**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product** : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging** : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good
14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Maritime transport in bulk according to IMO instruments
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Conditions of restriction for the following entries should be considered:
Number on list 3
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

Other regulations:
Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Posaconazole Injection Formulation

Version 6.4  Revision Date: 09.04.2021  SDS Number: 22513-00019  Date of last issue: 04.01.2021
Date of first issue: 16.10.2014

Full text of H-Statements

H317 : May cause an allergic skin reaction.
H319 : Causes serious eye irritation.
H361d : Suspected of damaging the unborn child.
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Irrit. : Eye irritation
Repr. : Reproductive toxicity
Skin Sens. : Skin sensitisation
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Posaconazole Injection Formulation

Version 6.4  Revision Date: 09.04.2021  SDS Number: 22513-00019  Date of last issue: 04.01.2021

Classification of the mixture:

<table>
<thead>
<tr>
<th>Classification</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin Sens. 1</td>
<td>H317</td>
</tr>
<tr>
<td>STOT RE 2</td>
<td>H373</td>
</tr>
<tr>
<td>Aquatic Chronic 3</td>
<td>H412</td>
</tr>
</tbody>
</table>

Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN